Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Cavo, Michele  [Clear All Filters]
Journal Article
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, et al. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. Eur J Haematol. 2021.
Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MTeresa, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, et al. Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. N Engl J Med. 2014;371(10):895-905.
Forte D, García-Fernández M, Sánchez-Aguilera A, Stavropoulou V, Fielding C, Martín-Pérez D, López JAntonio, Costa ASH, Tronci L, Nikitopoulou E, et al. Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy. Cell Metab. 2020.
Pantani L, Zamagni E, Zannetti BAnna, Pezzi A, Tacchetti P, Brioli A, Mancuso K, Perrone G, Rocchi S, Tosi P, et al. Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes. Ann Hematol. 2013.
Tacchetti P, Pantani L, Patriarca F, Petrucci MTeresa, Zamagni E, Dozza L, Galli M, Di Raimondo F, Crippa C, Boccadoro M, et al. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematol. 2020;7(12):e861-e873.
Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJosé, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, et al. Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. J Clin Oncol. 2013.
Cristiano G, Nanni J, Sartor C, Parisi S, Marconi G, Barbato F, Arpinati M, Bonifazi F, Curti A, Cavo M, et al. Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement. Acta Haematol. 2021:1-5.
Di Bacco A, Bahlis NJ, Munshi NC, Avet-Loiseau H, Masszi T, Viterbo L, Pour L, Ganly P, Cavo M, Langer C, et al. c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. Eur J Haematol. 2020.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, P Ho J, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2023.
Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, et al. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leuk Res. 2018;74:86-88.
Gentilini M, Casadei B, Broccoli A, Argnani L, Cavo M, Zinzani PLuigi. Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report. Acta Haematol. 2020:1-4.
Gugliotta G, Castagnetti F, Apolinari M, Pirondi S, Cavo M, Baccarani M, Rosti G. First-Line Treatment of Newly Diagnosed Elderly Patients with Chronic Myeloid Leukemia: Current and Emerging Strategies. Drugs. 2014.
Martinelli G, Papayannidis C, Piciocchi A, Robustelli V, Soverini S, Terragna C, Marconi G, Lemoli RMassimo, Guolo F, Fornaro A, et al. INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia. Blood Adv. 2021.
Palandri F, Palumbo GA, Benevolo G, Iurlo A, Elli EM, Abruzzese E, Polverelli N, Tiribelli M, Auteri G, Tieghi A, et al. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. Cancer. 2023.
Facon T, Moreau P, Martin TG, Spicka I, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yağci M, et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematol Oncol. 2022.
Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, et al. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. N Engl J Med. 2014;371(10):906-917.
Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH, et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2019.
Marconi G, Talami A, Abbenante MChiara, Sartor C, Parisi S, Nanni J, Bertamini L, Ragaini S, Olivi M, de Polo S, et al. Mec (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplantat in acute myeloid leukemia. Eur J Haematol. 2020.
Casadei B, Argnani L, Morigi A, Lolli G, Broccoli A, Pellegrini C, Nanni L, Stefoni V, Coppola PElia, Carella M, et al. Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: a real-life experience. Hematol Oncol. 2020.
Ludwig H, Terpos E, van de Donk N, Mateos M-V, Moreau P, Dimopoulos M-A, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24(6):e255-e269.
Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, et al. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. J Intern Med. 2019.
Palandri F, Breccia M, Tiribelli M, Bonifacio M, Benevolo G, Iurlo A, Elli EM, Binotto G, Tieghi A, Polverelli N, et al. RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA. Hematol Oncol. 2020.
Stanzani M, Lewis RE, Fiacchini M, Ricci P, Tumietto F, Viale P, Ambretti S, Baccarani M, Cavo M, Vianelli N. A Risk Prediction Score for Invasive Mold Disease in Patients with Hematological Malignancies. PLoS One. 2013;8(9):e75531.
Palandri F, Breccia M, Mazzoni C, Auteri G, Elli EMaria, Trawinska MM, Polverelli N, Tiribelli M, Benevolo G, Iurlo A, et al. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. Cancer. 2023.
Palandri F, Tiribelli M, Breccia M, Bartoletti D, Elli EM, Benevolo G, Martino B, Cavazzini F, Tieghi A, Iurlo A, et al. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer. 2021.

Pages